Diabetes Drug May Be Effective in Treating Parkinson’s

Image result for photo new research

Diabetes Drug May Be Effective in Treating Parkinson’s

Written by David Mills | Published on December 7, 2016                     Journal: Science Translational Medicine

Human trials are expected to begin next year on a drug researchers hope will be the first to slow the progression of Parkinson’s disease.

Can a drug that was originally designed to treat diabetes become the world’s first medication to slow the progress of Parkinson’s disease? Researchers are confident enough in the drug’s ability that they are organizing human clinical trials to begin next year.

“We hope this will be a watershed moment for millions of people living with Parkinson’s disease,” Dr. Patrik Brundin, director of Van Andel Institute’s Center for Neurodegenerative Science, chairman of The Cure Parkinson’s Trust’s Linked Clinical Trials committee, and the study’s senior author, said in a statement.

“The American Parkinson Disease Association (APDA) is always optimistic about studies that seek to slow the progression of the disease,” added Leslie A. Chambers, APDA president and chief executive officer, in an email to Healthline. “Well-designed randomized controlled clinical trials that assess new therapies are key in supporting this aspiration. We hope that a trial like this might offer promise for the future.”

Researchers said if the Parkinson’s human trials go well, the drug could someday be tested for possible treatment of other neurodegenerative diseases such as Alzheimer’s.

How the drug works

The drug, MSDC-0160, was designed by Michigan-based Metabolic Solutions Development Company to treat type 2 diabetes.

The drug showed the potential to regulate mitochondrial function in brain cells and restore the cells’ ability to convert basic nutrients into energy.

That enhances the cells’ ability to handle potentially harmful proteins, which leads to reduced inflammation and less nerve cell death.

Researchers said recently revived revelations that Parkinson’s may originate, at least partially, in the body’s energy metabolism led them to test MSDC-0160 on that disease.

After four years of positive results, the researchers said they are ready for human trials.

“Parkinson’s disease and diabetes may have vastly different symptoms with unrelated patient outcomes. However, we’re discovering they share many underlying mechanisms at the molecular level and respond similarly to a new class of insulin sensitizers like MSDC-0160,” Jerry Colca, Ph.D., co-founder, president, and chief scientific officer of MSDC, said in a statement.

The trials are also the latest in drug repurposing, a move in the scientific community to use medications that are effective on more than one ailment.

Search for a Parkinson’s cure

Parkinson’s disease affects more than 10 million people worldwide, including 1 million people in the United States.

There’s no cure for the ailment. Treatments now focus on symptom management.

Researchers say first-line treatment for Parkinson’s has remained relatively unchanged since the introduction of levodopa in the 1960s.

If it works, MSDC-0160 would be the first therapy to treat the underlying disease. That could result in fewer falls for patients as well as less cognitive decline.

In addition, it could delay the implementation of other Parkinson’s medications that can have serious side effects.

Tom Isaacs, a co-founder of The Cure Parkinson’s Trust who has lived with Parkinson’s for 22 years, said in a statement that MSDC-0160 represents one of the most promising treatments the trust’s international consortium has seen to date.

“Our scientific team has evaluated more than 120 potential treatments for Parkinson’s disease, and MSDC-0160 offers the genuine prospect of being a breakthrough that could make a significant and permanent impact on people’s lives in the near future,” said Isaacs. “We are working tirelessly to move this drug into human trials as quickly as possible in our pursuit of a cure.”

The Cure Parkinson’s Trust and Van Andel Institute are currently working with MSDC to address regulatory issues and obtain funding to organize the clinical trial, which Brundin hopes can begin sometime in 2017.



Leave a Reply

Donation Information

I would like to make a donation in the amount of:


I would like this donation to automatically repeat each month

Tribute Gift

Check here to donate in honor or memory of someone

Donor Information

First Name:
Last Name:
Add me to your mailing list

Donor Address

Address 2:(optional)
State :
Postal Code:

Shop with AmazonSmile and Support The NeuroCommunity Foundation

Did you know that you can support The NeuroCommunity Foundation through your everyday online purchases? Amazon.com has a charitable program called AmazonSmile. It is a simple and automatic way for you to support The NeuroCommunity Foundation every time you shop, at no cost to you.

When you shop at AmazonSmile, you’ll find the exact same low prices, vast selection and convenient shopping experience as Amazon.com, with the added bonus that the AmazonSmile Foundation will donate 0.5% of the purchase price to The NeuroCommunity Foundation!

It’s simple:

1) Go to AmazonSmile from the web browser on your computer or mobile device.
2)Login with your amazon.com username and password or create one if you are a new user.
3) Search for The NeuroCommunity Foundation in the search box on the right side where it asks which charity you would like to support.
4) Select The NeuroCommunity Foundation from the search results or type in The NeuroCommunity Foundation should the select not include our organization.
Happy shopping and thank you for supporting The NeuroCommunity Foundation

Support us when you shop for back-to-school items.

Just Click Here and Shop

Northridge Foundation For Neurological Research & Education

Smile with Back to School shopping

Dear The NeuroCommunity Foundation friends,supporters and participants.

If you happen to shop at Ralphs and would like to support The NeuroCommunity Foundation, we would be most appreciative!. If you do shop at Ralphs, we will receive 1 % of your purchase through their community
contribution program. The NeuroCommunity Foundation's Non-Profit Org. number ( NP0 # ) is 82287

All you need to do is enroll online at www.ralphs.com OR by calling Ralphs at
800-443-4438 after September 1, 2016.

If you happened to enroll prior to Sept 1st, Ralphs requires you to register again.

For your convenience, step-by-step website registration instructions are found below or can be found at www.ralphs.com, click on Community, click on Community Contributions, click on ‘Enroll Now’. If you don’t have computer access, please call us at 1-800-443-4438 for assistance.

Use you Ralph’s Rewards Card to Contribute Here’s How:

If you do not have a Ralph’s online account
1. Go to www.ralphs.com/account/create
2. Follow the easy steps to create an online account
3. You will be instructed to go to your email inbox to confirm your account
4. After you confirm your online account by clicking on the link in your email, return to
www.ralphs.com and click on ‘Sign In’, enter your email address and password.
5. View all your information and edit as necessary
6. Link your card to your organization by clicking on:
a. Community Rewards – Enroll
b. Type our NPO number 82287 or Neurocommunity.org
c. Remember to click on the circle to the left of your organizations’ name
d. Click on Enroll to finish your enrollment process

(This means that you have already entered your email address and assigned yourself a password)

1. Log in to www.ralphs.com
2. Click Sign In
3. Enter your email address and password
4. Click on ‘Your Name’ (In the top right hand corner)
5. View all your information and edit as necessary
6. Link your card to your organization by clicking on:
a. Community Rewards – Re-Enroll
b. Type your NPO number or Name of your Organization
c. Remember to click on the circle to the left of your organizations’ name
d. Click on Enroll to finish your enrollment process